Safer and better performing bone graft substitute
15.09.2023 BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd
13.09.2023 BBS-Bioactive Bone Substitutes Plc – Insider information: Plan to complete minor open issues approved – the Company updates its outlook on the schedule of the CE marking
04.09.2023 BBS-Bioactive Bone Substitutes has resolved on a share issue without consideration to the company itself
Full preclinical safety and performance package as a medical device
Almost 3 million bone graft operations annually worldwide